Cargando…

Complement Activation in the Treatment of B-Cell Malignancies

Unconjugated monoclonal antibodies (mAb) have revolutionized the treatment of B-cell malignancies. These targeted drugs can activate innate immune cytotoxicity for therapeutic benefit. mAb activation of the complement cascade results in complement-dependent cytotoxicity (CDC) and complement receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zent, Clive S., Pinney, Jonathan J., Chu, Charles C., Elliott, Michael R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709106/ https://www.ncbi.nlm.nih.gov/pubmed/33271825 http://dx.doi.org/10.3390/antib9040068

Ejemplares similares

Persistent polyclonal B‐cell lymphocytosis: Illustration of the great mimicker of low‐grade B‐cell lymphoma
por: Nkosi, Dingani, et al.
Publicado: (2022)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

ON COMPLEMENT-FIXATION IN MALIGNANT DISEASE
por: Simon, Charles E., et al.
Publicado: (1908)

Components of the Lectin Pathway of Complement in Haematologic Malignancies
por: Cedzyński, Maciej, et al.
Publicado: (2020)

Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
por: Felberg, Anna, et al.
Publicado: (2020)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
por: Oostindie, Simone C., et al.
Publicado: (2019)

Differentiation of Chronic Lymphocytic Leukemia B Cells into Immunoglobulin Secreting Cells Decreases LEF-1 Expression
por: Gutierrez, Albert, et al.
Publicado: (2011)

Complement activation in IgA nephropathy
por: Medjeral-Thomas, Nicholas R., et al.
Publicado: (2021)

Immunomodulatory Drugs for the Treatment of B Cell Malignancies
por: Ioannou, Nikolaos, et al.
Publicado: (2021)

Cell-bound complement activation products in SLE
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2017)

Targeting CD22 for the Treatment of B-Cell Malignancies
por: Shah, Nikesh N, et al.
Publicado: (2021)

Endothelial-derived complement factor D contributes to endothelial dysfunction in malignant nephrosclerosis via local complement activation
por: Wang, Zheng, et al.
Publicado: (2023)

Complexity of complement activation in sepsis
por: Markiewski, Maciej M, et al.
Publicado: (2008)

Cross-Complementation Study of the Flagellar Type III Export Apparatus Membrane Protein FlhB
por: Barker, Clive S., et al.
Publicado: (2012)

Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies
por: Efremov, Dimitar G., et al.
Publicado: (2020)

Purified complement C3b triggers phagocytosis and activation of human neutrophils via complement receptor 1
por: Boero, Elena, et al.
Publicado: (2023)

Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

The B Cell Receptor Itself Can Activate Complement to Provide the Complement Receptor 1/2 Ligand Required to Enhance B Cell Immune Responses In Vivo
por: Rossbacher, Joerg, et al.
Publicado: (2003)

COMPLEMENT AND COMPLEMENT-LIKE ACTIVITY IN LOWER VERTEBRATES AND INVERTEBRATES
por: Day, N. K. B., et al.
Publicado: (1970)

Targeting the Complement Pathway in Malignant Glioma Microenvironments
por: Zhu, Hongtao, et al.
Publicado: (2021)

Complement in neurological disorders and emerging complement-targeted therapeutics
por: Dalakas, Marinos C., et al.
Publicado: (2020)

The potential of pirtobrutinib in multiple B-cell malignancies
por: Jensen, Jeffrey L., et al.
Publicado: (2022)

Ibrutinib for B cell malignancies
por: Novero, Aileen, et al.
Publicado: (2014)

Targets for Ibrutinib Beyond B Cell Malignancies
por: Berglöf, A., et al.
Publicado: (2015)

Increased Complement Activation in Human Type 1 Diabetes Pancreata
por: Rowe, Patrick, et al.
Publicado: (2013)

Mammalian Non-CpG Methylation: Stem Cells and Beyond
por: Pinney, Sara E.
Publicado: (2014)

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
por: Hainsworth, John D
Publicado: (2003)

MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
por: Marques, Sara Correia, et al.
Publicado: (2014)

The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking
por: Lenkiewicz, Anna, et al.
Publicado: (2019)

Effects of high glucose on integrin activity and fibronectin matrix assembly by mesangial cells
por: Miller, Charles G., et al.
Publicado: (2014)

Complement and Complement Targeting Therapies in Glomerular Diseases
por: Andrighetto, Sofia, et al.
Publicado: (2019)

The complement system
por: Sarma, J. Vidya, et al.
Publicado: (2010)

Enhancing B-Cell Malignancies—On Repurposing Enhancer Activity towards Cancer
por: Kasprzyk, Marta Elżbieta, et al.
Publicado: (2021)

Genetic variability shapes the alternative pathway complement activity and predisposition to complement‐related diseases
por: Rodríguez de Córdoba, Santiago
Publicado: (2022)

Complementing Testicular Immune Regulation: The Relationship between Sertoli Cells, Complement, and the Immune Response
por: Washburn, Rachel L., et al.
Publicado: (2023)

Aberrant Complement System Activation in Neurological Disorders
por: Ziabska, Karolina, et al.
Publicado: (2021)

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic
por: Lin, Victor S., et al.
Publicado: (2020)

Dysregulation of Small Nucleolar RNAs in B-Cell Malignancies
por: Verbeek, Martijn W. C., et al.
Publicado: (2022)

Treading & threading memories: a personal encounter with forest and people in Southern Venezuela
por: Zent, Egleé L
Publicado: (2013)

Complement Activation and Inhibition in Wound Healing
por: Cazander, Gwendolyn, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_k7st0p79p6eds1bttg3jdkus6i